NCT05972018View on ClinicalTrials.gov

Liposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters

PHASE4RecruitingINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 18, 2023

Primary Completion Date

October 30, 2026

Study Completion Date

December 30, 2026

Conditions
Aortic Aneurysm, AbdominalAbdominal Aortic OcclusionAortoiliac Occlusive DiseaseAortic Diseases
Interventions
DRUG

Liposomal bupivacaine

Rectus Sheath Block: Total 60mL: (20mL 1.3% Liposomal bupivacaine + 30mL 0.25% bupivacaine + 10mL NS).(30mL per side)

DRUG

Ropivacaine

Total 60mLof 0.2% ropivacaine: (60mL of 0.2% ropivacaine (3 vials)

DRUG

Bupivacain

Rectus Sheath Block: Total 60mL: (20mL 1.3% LB + 30mL 0.25% bupivacaine + 10mL NS. 30mL per side)

Trial Locations (1)

06102

RECRUITING

Hartford Hospital, Hartford

All Listed Sponsors
lead

Hartford Hospital

OTHER